Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
11,734
Total Claims
$853K
Drug Cost
608
Beneficiaries
$1,403
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+47%
Opioid rate vs peers
3.8% vs 2.6% avg
+31%
Cost per patient vs peers
$1,403 vs $1,068 avg
+54%
Brand preference vs peers
13.9% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
3.8%
Opioid Rate
446
Opioid Claims
$11K
Opioid Cost
12.1%
Long-Acting Rate
Brand vs Generic
Brand: 1,622 claims · $640K
Generic: 10,050 claims · $210K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 132 | $81K |
| Dulaglutide | 54 | $52K |
| Rivaroxaban | 61 | $33K |
| Empagliflozin | 45 | $29K |
| Mirabegron | 76 | $26K |
| Sitagliptin Phosphate | 46 | $22K |
| Dapagliflozin Propanediol | 26 | $22K |
| Eluxadoline | 12 | $20K |
| Fluticasone/Umeclidin/Vilanter | 28 | $20K |
| Fluticasone/Vilanterol | 45 | $19K |
| Insulin Glargine,hum.Rec.Anlog | 17 | $17K |
| Umeclidinium Brm/Vilanterol Tr | 33 | $16K |
| Insulin Regular, Human | 13 | $16K |
| Insulin Lispro | 20 | $16K |
| Insulin Glargine,hum.Rec.Anlog | 23 | $14K |
Prescribing Profile
Patient Profile
76
Avg Age
58%
Female
1.02
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About